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Cancer incidence and mortality rates and
trends in Trinidad and Tobago
Wayne A. Warner1,2,16* , Tammy Y. Lee3, Kimberly Badal4, Tanisha M. Williams5, Smriti Bajracharya6,
Vasavi Sundaram7, Nigel A. Bascombe8, Ravi Maharaj8, Marjorie Lamont-Greene9, Allana Roach10, Melissa Bondy11,
Matthew J. Ellis11, Timothy R. Rebbeck12, Simeon Slovacek3, Jingqin Luo13,14, Adetunji T. Toriola14
and Adana A. M. Llanos15,17*

Abstract
Background: Cancer is the second leading cause of death in the Caribbean, including the islands of Trinidad
and Tobago (TT). The population of TT consists of over 1.3 million people with diverse ancestral and sociocultural
backgrounds, both of which may influence cancer incidence and mortality. The objective of this study was to
examine incidence and mortality patterns and trends in TT.
Methods: Cancer surveillance data on 29,512 incident cancer cases reported to the Dr. Elizabeth Quamina Cancer
Registry (population-based cancer registry of TT) between 1995 and 2009 were analyzed. Age-standardized rates,
overall and by sex, ancestry, and geography, were reported.
Results: The highest incidence and mortality rates were observed for cancers related to reproductive organs in women,
namely, breast, cervical, and uterine cancers, and prostate, lung and colorectal cancers among men. Average incidence rates
were highest in areas covered by the Tobago Regional Health Authority (TRHA) (188 per 100,000), while average mortality
rates were highest in areas covered by the North West Regional Health Authority (108 per 100,000). Nationals of African
ancestry exhibited the highest rates of cancer incidence (243 per 100,000) and mortality (156 per 100,000) compared to their
counterparts who were of East Indian (incidence, 125 per 100,000; mortality, 66 per 100,000) or mixed ancestry (incidence,
119 per 100,000; mortality, 66 per 100,000).
Conclusions: Our findings highlight the need for national investment to improve the understanding of the epidemiology of
cancer in Trinidad and Tobago, and to ultimately guide much needed cancer prevention and control initiatives in the near
future.
Keywords: Trinidad and Tobago, Caribbean, Cancer incidence, Cancer mortality, Cancer surveillance, Cancer in populations
of African ancestry, Cancer in populations of Indian ancestry

Background
Cancer is the second leading cause of death in the
Caribbean and has created tremendous challenges for
healthcare services and expenditures throughout the
region [1]. The World Health Organization (WHO) projects that cancer incidence will increase by 58%, from
84,703 cases in 2015 to 133,937 cases in 2035, and
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cancer mortality will increase by 67% during this period,
from 52,282 to 87,430 deaths [2]. Aging of the population, improvements in healthcare and economic development has led to a higher prevalence of lifestyle-related
risk factors for cancer, including reproductive behaviors,
dietary patterns, physical inactivity, obesity, and alcohol
and tobacco use. In addition, the prevalence of
cancer-associated viral infections (e.g., human papillomavirus, human herpesvirus-8 (HHV8), human T-cell
lymphotropic virus-1 (HTLV-1), hepatitis B virus
(HBV)), may be higher among Caribbean populations
compared to United States (US) populations [3, 4].
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In the twin island nation of Trinidad and Tobago
(TT), cancer is a leading cause of death much like the
rest of the Caribbean [5]. These English-speaking islands
are unique in terms of their economy and ancestry. TT,
located off the northeastern edge of South America, is
one of the richest countries by gross domestic product
(GDP) per capita in the Americas and is classified as a
high-income economy by the World Bank [6]. This is
due to the nation’s industrialized economy, which includes petroleum, natural gas, chemical industries, and
food and beverage industries [7]. While TT is classified
as a developing country by the International Monetary
Fund (IMF) [8] and is a member of the United Nations
Conference of Small Island Developing States (SIDS) [9],
this nation faces major challenges in its efforts to
achieve developed nation status in sectors such as
healthcare [10]. TT’s estimated population is 1.4 million
[11] with an average life expectancy of 74.61 years [12].
From 1990 to 2010, the demographic profile of TT
underwent a transition marked by a declining fertility
rate, a decrease in the < 15 years age-group, and a doubling of the > 60 years age-group [5]. While the Trinidad
population consists of diverse ancestral groups (including African (31.76%), East Indian (37.01%), Mixed ancestry (23.52%), Chinese, White, and Syrian/Lebanese (<
1%)), as well as religious groups (including Christian,
Muslim, and Hindu), the population in Tobago is predominantly of African ancestry (85.29%) and Christian
[11, 12]. These demographic patterns have resulted in
customs and traditions that have marked the sociocultural development of the islands [13]. Hence, research
on the epidemiology and etiology of cancers in TT, in
relation to the environment, lifestyle and ancestry, is essential for the success of cancer prevention and control
programs and policies.
The literature on the burden of cancer within TT remains
relatively barren. Previous studies of cancer in TT have reported site-specific cancer incidence, mortality and survival
rates, including for breast, prostate, and gastric cancers [14–
19]. However, a comprehensive analysis of cancer incidence
and mortality has never been reported. Since 1994, the Dr.
Elizabeth Quamina Cancer Registry has served as the National Cancer Registry of TT, using standard cancer registry
guidelines and statistical methods [20, 21].
Here, we present on cancer incidence and mortality
rates and trends in TT for the overall population, and by
sex, geography, ancestry, and age. This is the first epidemiologic examination of cancer rates and trends across
all cancer sites in TT for the period 1995 to 2009.

Methods
We obtained retrospectively collected cancer surveillance data (incidence and mortality) reported between
January 1, 1995 and December 31, 2009 to the National
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Cancer Registry of TT, which represents all of the most
current and available data from the cancer registry. The
analytic dataset consisted of the 29,512 incident cancers
(pediatric and adult cases) reported during the study
period. The source of the registry records was previously
described [18]. In brief, the registry abstracts data from
private and public hospitals across Trinidad and Tobago
including all of the main cancer treatment centers. Abstracted data included place of residence, age, sex, ancestry, stage, grade and method of cancer detection. In the
registry data file, cancer histology was coded based on
WHO International Classification of Diseases for Oncology (ICD-O) code C61.9. as supplied by the healthcare
institutions [22]. The boundaries for the geographic analysis by corporation and Regional Health Authority
(RHA) were previously described [18]. In brief, TT is divided into fifteen governmental administrative corporations and five RHAs for healthcare delivery and
administration. Self-identification, medical records, and
to a lesser extent, imputation by binary logistic regression were used to determine ancestry [18].
Death certification and population data were obtained
from the Trinidad and Tobago Central Statistical Office
(CSO) 2000 and 2010 census. The population pyramids
for 2000 and 2011 were previously described [11, 12].
Populations estimates for the other study years were calculated through interpolation using the “irregular points
of year” estimation method [20, 21]. The CSO collects
several population measures including age (single year of
age, 5- and 10-year age groups), ethnicity, and sex. From
these data points, we calculated the age-standardized incidence and mortality rates (per 100,000 TT population)
by age (10-year), sex, geography, ancestry, and individual
years based on the 1960 world-standardized population
[23, 24]. This methodology was selected for ease of comparison with the International Agency for Research on
Cancer (IARC) data which uses the same
standardization. The TT case fatality rate was calculated
by dividing the number of cancer deaths over the study
period by the number of incident cases and then multiplying the resultant ratio by 100 to yield a percentage.
For the period 1995–2007, the average time between
cancer incidence and cancer death was calculated by taking the average length of the time from the year of incidence to the year of death for the 15,279 cancer deaths
recorded during the same time period. For the same
time period, the mean survival time (among cancer cases
reported in the registry as still living at last contact,
N = 10,087) was calculated by taking the average of
the time from incidence to date of last contact. The
geospatial maps were rendered in the R computing
environment [25] and Statistical Package of Social
Science (SPSS) V.20 (IBM Corporation, Valhalla, NY)
was used for analyses.
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Results
Cancer incidence and mortality rates among men and
women

The number and percentage of cancer cases and deaths,
along with age-standardized cancer incidence and mortality rates are shown in Table 1. Between 1995 and
2009, there were a total of 29,512 incident primary cancers and 18,216 cancer deaths in TT, with an overall
case-fatality rate of 61.7%. For this time period, the average length of time between diagnosis and death was
1 year (range: less than 1 year to 40 years) and the average survival time among living cases was 1.1 year (range:
less than 1 year to 14 years). Several basic metrics of
data quality from the registry are provided (Additional file 1: Table S1). Of note, the percent of cases registered only on the basis of the death certificate only
(DCO) fluctuated from 12.12% in 1995 to 27.63% in
2000 to 10.48% in 2005 and then to 6.32% in 2009. The
average over the study period was 18.44%.
Overall, cancer incidence and mortality rates were 13.4
and 22.3% higher, respectively, among men than women.
Cancer incidence and mortality trends by sex in TT are
shown in Fig. 1. The overall age-standardized cancer incidence rate among TT men was 159.7 per 100,000,
while the overall mortality rate was 103.8 per 100,000.
The most commonly diagnosed cancers among men
were prostate (64.0 per 100,000), lung and bronchus
(15.9 per 100,000), colon (11.6 per 100,000), hematologic
(11.4 per 100,000) and stomach (6.5 per 100,000). Similarly, the cancers with the highest mortality rates among
men were prostate (37.5 per 100,000), lung and bronchus (12.7 per 100,000), hematologic (8.2 per 100,000),
colon (7.6 per 100,000) and stomach cancer (5.3 per
100,000).
Among
TT
women,
the
overall
age-standardized cancer incidence rate was 146.3 per
100,000, while the overall mortality rate was 81.5 per
100,000. The most commonly diagnosed cancers among
women were breast (46.6 per 100,000), cervix uteri (18.1
per 100,000), corpus uteri (13.4 per 100,000),
hematologic (9.1 per 100,000), colon (9.0 per 100,000)
and ovarian cancer (8.9 per 100,000). The cancers with
the highest mortality were breast (18.4 per 100,000), cervix uteri (9.7 per 100,000), corpus uteri (6.4 per
100,000), hematologic (6.5 per 100,000) and ovarian (5.8
per 100,000) (Table 1A, B).
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responsible for direct provision of healthcare services in
their respective catchment area [18]. As shown in Fig. 2,
age-standardized cancer incidence and mortality rates
varied by RHA. Average incidence rates were highest in
areas covered by the TRHA (188 per 100,000), followed
by NWRHA (173 per 100,000), and NCRHA (153 per
100,000), compared to ERHA (139 per 100,000) and
SWRHA (131 per 100,000). Overall, average mortality
rates were highest in areas covered by NWHRA (108 per
100,000), followed by NCRHA and TRHA, (94 and 91
per 100,000, respectively). The NWRHA covers the area
that includes the capital city of Port-of-Spain, which had
the highest overall age-standardized cancer incidence
(238 per 100,000) and mortality (151 per 100,000). Corporations within the SWRHA catchment area, Penal and
Debe (110 per 100,000) and Couva, Tabaquite, and Talparo (119 per 100,000) had among the lowest overall
cancer incidence rates. Penal and Debe had the lowest
cancer mortality (59 per 100,000).
Cancer incidence and mortality by ancestry

The highest cancer incidence (243 per 100,000) and
mortality (156 per 100,000) rates were observed among
individuals of African ancestry compared to Indian or
mixed ancestry (Fig. 3). Cancer incidence and mortality
rates by sex, ancestry, and age in TT are shown in Fig. 4.
The highest burden of cancer for both men and women
were observed among those ≥45 years. Among TT men,
cancers with the highest incidence and mortality (prostate, colon, hematologic and stomach cancers) were observed among those 65–74 years (Fig. 4a-e). However,
the highest lung cancer rates were observed among
those aged 55–64 years (Fig. 4b). Among TT women,
the highest breast and cervical cancer incidence and
mortality rates were observed among those 45–54 years
(Fig. 4f-j). Women 55–64 years experienced the highest
corpus uteri incidence, while colon cancer and ovarian
cancer occurred most frequently among women 65–
74 years (Fig. 4h-j). The highest mortality rates for corpus uteri cancer were observed among women 55–
64 years, while the highest mortality rates for colon and
ovarian cancers were observed for women 65–74 years
(Fig. 4h-j). Incidence and mortality data for those under
24 is provided (Additional file 2: Table S2).
Stage distribution of selected cancers

Cancer incidence and mortality rates by geography

The geographical area of residence corresponded with
Ministry of Health RHAs (Fig. 2). There are five RHAs
in TT – North West Regional Health Authority
(NWRHA); North Central Regional Health Authority
(NCRHA); South West Regional Health Authority
(SWRHA); Eastern Regional Health Authority (ERHA);
and Tobago Regional Health Authority (TRHA) –

Figure 5 shows the distribution of stage at diagnosis among
the leading cancers by sex and ancestry. Most prostate cancers were diagnosed at localized stage (African 42%, Indian
46%, and mixed ancestry 39%). More than 15% of lung and
bronchus (African 21%, Indian 19%, and mixed ancestry
33%) and stomach cancers (African 18%, Indian 19%, and
mixed ancestry 28%) occurred in the distant stage. Less
than 15% of breast (African 10%, Indian 6%, and mixed
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Table 1 Counts, percentages, and age-standardized incidence (A) and mortality (B) rates per 100,000 for adult and pediatric cancers,
Trinidad and Tobago, 1995–2009
(A) Incidence
Cancer site

Both sexes

Men

Women

ICD-10 codes

Count (%)

ASR(W)
Rate

Count (%)

ASR(W)
Rate

Count (%)

ASR(W)
Rate

C40, C41

156 (0.8%)

0.8

95 (0.6%)

0.9

61 (0.4%)

0.6

Brain & other nervous system

C70 – C72

370 (1.9%)

2.0

222 (1.5%)

2.5

148 (1.0%)

1.6

Breast

C50

4685
(24.6%)

46.6#

72 (0.5%)

0.8

4613
(31.6%)

46.6

Digestive system

C15 – C26

5967
(31.3%)

30.5

3340
(22.4%)

36.0

2627
(18.0%)

25.3

Colon

C18

2023 (10.6%)

10.3

1084 (7.3%)

11.6

939 (6.4%)

9.0

Liver

C22

432 (2.3%)

2.2

242 (1.6%)

2.6

190 (1.3%)

1.8

Pancreas

C25

902 (4.7%)

4.6

489 (3.3%)

5.3

413 (2.8%)

3.9

Rectum

C20

620 (3.3%)

3.2

358 (2.4%)

3.9

262 (1.8%)

2.6

Bones & joints

Stomach

C16

999 (5.2%)

5.0

607 (4.1%)

6.5

392 (2.7%)

3.7

Othera

C15, 17, 19, 21, 23, 24,
26

991 (5.2%)

4.2

560 (3.7%)

5.0

431 (3.0%)

3.5

Endocrine system

C73 – C75

241 (1.3%)

1.2

73 (0.5%)

0.8

168 (1.2%)

1.6

Eye & orbit

C69

38 (0.2%)

0.3

25 (0.2%)

0.3

13 (0.1%)

0.2

Hematologicb

C42, C77

1949
(10.2%)

10.3

1062 (7.1%)

11.4

887 (6.1%)

9.1

Oral cavity & pharynx

C00 – C14

744 (3.9%)

3.9

532 (3.6%)

5.8

212 (1.5%)

2.1

Reproductive system

C51 – C63

–

–

6233
(41.7%)

65.7

4221
(29.0%)

42.9

Penis

C60

–

–

87 (0.6%)

0.8

–

–

Prostate

C61

–

–

6064 (40.6%)

64.0

–

–

Testis

C62

–

–

79 (0.5%)

0.7

–

–

Other male genitals

C63

–

–

3 (0.0%)

0.0

–

–

Cervix uteri

C53

–

–

–

–

1812 (12.4%)

18.1

Corpus uteri

C54

–

–

–

–

1275 (8.7%)

13.4

Ovary

C56

–

–

–

–

885 (6.1%)

8.9

Vagina

C52

–

–

–

–

81 (0.6%)

0.6

Vulva

C51

–

–

–

–

59 (0.4%)

0.6

Other female genitals

C55, C58, C63

–

–

–

–

109 (0.7%)

0.8

C30 – C34, C37– C39

2408
(12.6%)

12.5

1907
(12.8%)

20.7

501 (3.4%)

4.9

Respiratory system
Larynx

C32

343 (1.8%)

1.8

321 (2.1%)

3.5

22 (0.2%)

0.2

Lung bronchus

C34

1857 (9.7%)

9.7

1460 (9.8%)

15.9

397 (2.7%)

3.9

Otherc

C30, 31, 33, 37, 38

208 (1.1%)

0.9

126 (0.8%)

1.2

82 (0.6%)

0.7

C44

398 (2.1%)

2.0

234 (1.6%)

2.5

164 (1.1%)

1.6

Skin (excluding basal &
squamous)
Soft tissue (including heart)

C47 – C49

274 (1.4%)

1.4

151 (1.0%)

1.6

123 (0.8%)

1.3

Urinary system

C64 – C68

682 (3.6%)

3.6

443 (3.0%)

4.9

239 (1.6%)

2.5

Ill-defined & unknown

C76, C80

TOTALd
(B) Mortality
Cancer site

Bones & joints

1146 (6.0%)

5.9

547 (3.7%)

5.9

599 (4.1%)

5.9

19,058

98.5

14,936

159.7

14,576

146.3

Overall

Men

Women

ICD-10 codes

Count (%)

ASR(W)
Rate

Count (%)

ASR(W)
Rate

Count (%)

ASR(W)
Rate

C40, C41

92 (0.8%)

0.5

56 (0.6%)

0.5

36 (0.4%)

0.4
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Table 1 Counts, percentages, and age-standardized incidence (A) and mortality (B) rates per 100,000 for adult and pediatric cancers,
Trinidad and Tobago, 1995–2009 (Continued)
(A) Incidence
Cancer site
Brain & other nervous system

Both sexes

Men

Women

ICD-10 codes

Count (%)

ASR(W)
Rate

Count (%)

ASR(W)
Rate

Count (%)

ASR(W)
Rate

C70 – C72

206 (1.1%)

1.1

117 (1.2%)

1.3

89 (1.1%)

0.9

#

Breast

C50

1990
(16.5%)

19.2

35 (0.4%)

0.4

1955
(23.5%)

19.2

Digestive system

C15 – C26

4459
(36.9%)

22.4

2502
(25.3%)

26.7

1957
(23.5%)

18.4

C18

1331 (11.0%)

6.6

719 (7.3%)

7.6

612 (7.4%)

5.7

Colon
Liver

C22

400 (3.3%)

2.0

223 (2.3%)

2.4

177 (2.1%)

1.6

Pancreas

C25

796 (6.6%)

4.0

436 (4.4%)

4.7

360 (4.3%)

3.4

Rectum

C20

338 (2.8%)

1.7

199 (2.0%)

2.1

139 (1.7%)

1.3

Stomach

C16

841 (7.0%)

4.2

503 (5.1%)

5.3

338 (4.1%)

3.2

C15, 17, 19, 21, 23, 24,
26

753 (6.2%)

3.8

422 (4.3%)

4.5

331 (4.0%)

3.2

Endocrine system

C73 – C75

125 (1.0%)

0.6

42 (0.4%)

0.5

83 (1.0%)

0.8

Eye & orbit

C69

11 (0.1%)

0.1

6 (0.1%)

0.1

5 (0.1%)

0.1

Hematologicb

C42, C77

1407
(11.6%)

7.3

769 (7.8%)

8.2

638 (7.7%)

6.5

Oral cavity & pharynx

C00 – C14

446 (3.7%)

2.3

330 (3.3%)

3.6

116 (1.4%)

1.2

Reproductive system

C51 – C63

–

–

3772
(38.1%)

38.2

2356
(28.3%)

23.5

C60

–

–

37 (0.4%)

0.4

–

–

a

Other

Penis
Prostate

C61

–

–

3704 (37.4%)

37.5

–

–

Testis

C62

–

–

29 (0.3%)

0.3

–

–

Other male genitals

C63

–

–

2 (0.0%)

0.0

–

–

Cervix uteri

C53

–

–

–

–

974 (11.7%)

9.7

Corpus uteri

C54

–

–

–

–

632 (7.6%)

6.4

Ovary

C56

–

–

–

–

582 (7.0%)

5.8

Vagina

C52

–

–

–

–

42 (0.5%)

0.4

Vulva

C51

–

–

–

–

38 (0.5%)

0.4

C55, C58, C63

–

–

–

–

87 (1.0%)

0.8

C30 – C34, C37– C39

1777
(14.7%)

9.2

1409
(14.2%)

15.2

368 (4.4%)

3.6

Larynx

C32

184 (1.5%)

0.9

174 (1.8%)

1.8

10 (0.1%)

0.1

Lung bronchus

C34

1477 (12.2%)

7.7

1162 (11.7%)

12.7

315 (3.8%)

3.1

Otherc

C30, 31, 33, 37, 38

116 (1.0%)

0.6

73 (0.7%)

0.7

43 (0.5%)

0.4

Skin (excluding basal &
squamous)

C44

141 (1.2%)

0.7

83 (0.8%)

0.9

58 (0.7%)

0.5

Soft tissue (including heart)

C47 – C49

140 (1.2%)

0.8

83 (0.8%)

0.9

57 (0.7%)

0.6

Urinary system

C64 – C68

419 (3.5%)

2.1

276 (2.8%)

3.0

143 (1.7%)

1.4

Ill defined & unknown

C76, C80

875 (7.2%)

4.4

416 (4.2%)

4.4

459 (5.5%)

4.4

12,088

61.5

9896

103.8

8320

81.5

Other female genitals
Respiratory system

d

TOTAL

NOTE: Percentages may not sum to 100% due to rounding. Information refering to major organ systems are bolded
a
Anus, anal canal, bile tract, esophagus, gall bladder, gastrointestinal, rectosigmoid junction, small intestine
b
Myeloma, lymphoma, leukemia
c
Accessory sinus, ear/nose, heart, pleura, respiratory tract, thymus, trachea
d
Excludes genital cancer

Warner et al. BMC Cancer (2018) 18:712
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a

b

c

d

Fig. 1 Trends in rates for selected cancers by sex, Trinidad and Tobago, 1995 to 2009. Rates are age adjusted to the 1960 world standard
population. a, b incidence and mortality cancer rates for men and (c, d) incidence and mortality cancer rates for women

ancestry 8%) and cervix uteri cancers (African 10%, Indian
6%, and mixed ancestry 8%) occurred in the distant stage.
More than 30% of all ovarian cancers (African 36%, Indian
27%, and mixed ancestry 31%) occurred in the distant stage.
Strikingly, across all sites, there was a high percentage (12–
57%) of cancers with unknown stage.

Discussion
This is the first epidemiologic study to examine TT cancer rates and trends across all cancer sites, by age, ancestry, geography and sex, with a focus on the cancers with
highest incidence rates. We found that incident cases of
prostate, lung, colon, stomach, and hematologic cancers
were most common among men, while among women,
the cancers with the highest incidence were breast,

cervical, endometrial, colon, and ovarian. Overall, the incidence rates were highest in Tobago and the area covered by the NWRHA (which contains the capital city of
Port-of-Spain), while cancer mortality was highest in
NWRHA. The highest incidence and mortality rates
were observed among adults aged ≥45 years. Except cervical and breast cancers, most cancers had a significant
proportion of cases (> 10%) diagnosed at distant stage
and all cancers except breast had > 20% with unknown
stage. TT nationals of African ancestry had the highest
incidence and mortality rates. The high overall
case-fatality rate reflects the need for improved strategies to reduce cancer mortality in TT.
Evidence suggests that many of the most prevalent
cancers among men and women in TT are likely
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Fig. 2 Geospatial maps of cancer incidence and mortality rates in Trinidad and Tobago 1995–2009: (Top panel, left to right) Age-standardized
incidence rates for all (a) Regional Health Authorities and (b) Corporations, and age-standardized mortality rates for all (c) Regional Health Authorities
and (d) Corporations. Rates are age adjusted to the 1960 world standard population. H, Hospital

Fig. 3 Overall cancer incidence and mortality rates in Trinidad and Tobago by ancestry, 1995–2009. Rates are age adjusted to the 1960 world
standard population
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Fig. 4 Age-standardized incidence and mortality rates for the leading cancer sites by sex (a-e, male; f-j, female), ancestry (purple, African ancestry;
orange, Indian ancestry; gray, Mixed ancestry), and age groups, Trinidad and Tobago, 1995–2009. All bars are uniformly scaled. Data for persons
under 24 are presented in Additional file 2: Table S2
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Fig. 5 Stage distribution of selected cancers by sex, Trinidad and Tobago, 1995–2009. Stage categories may not sum to 100% because of rounding

attributable to preventable lifestyle factors (e.g., associated with the “westernized lifestyle” of developed countries). Tobacco use, obesity, pathogens, physical
inactivity, diet, and alcohol are among the known lifestyle factors associated with increased cancer incidence
[26–29]. A recent study in TT reported that the current
prevalence of tobacco use among men (33.5%) is significantly higher than among women (9.4%), which may
contribute to the higher rate of lung cancer among men
[30]. Additionally, the study found that the overall mean
body mass index (BMI) for women and men in TT was
27.4 kg/m2 and 25.6 kg/m2, respectively, and that >
55.7% of the population was overweight or obese (BMI
≥25) [30]. A recent IARC working group comprehensive
review of multiple datasets, concluded that excess body
fat causes cancer in multiple anatomical sites, including
those identified in this study as placing the highest burden in TT [31, 32]. Numerous studies have reported the
causal relationship between physical inactivity and cancer [33–35], and while the amount of total physical activity (PA) required to lower the risk of specific cancers
in a dose-response fashion has not been established, the
WHO recommends at least 600 metabolic equivalents of
task (MET) minutes/week for health benefits [36]. Strikingly, a recent study in TT reported that the median PA
approximated 300.30 (MET minutes/week) (median,
149.1 MET minutes/week) [30]. Focused cancer prevention initiatives in TT targeting obesity reduction and an
increase in PA might have value in reducing the risk of
cancer.

The TT population of African ancestry suffers a higher
cancer burden across all cancer sites. This is similar to
studies reporting that members of the African diaspora
suffer a disproportionate cancer burden compared to
other groups [37, 38]. Interestingly, we found that in
Tobago, with its relatively homogeneous African ancestry population, there was a higher overall cancer incidence rate (187.7 per 100,000), driven primarily by the
incidence rates of breast and prostate cancers. Surprisingly, while the incidence rates are high, mortality rates
are relatively low (91.3 per 100,000). Further exploration
is needed to evaluate the causes of the excess cancer
burden, which may include genetic variation, tumor
biology, and additional factors that have been understudied in the TT population. The contribution of tumor
biology, genomics, comorbidities and patterns of care to
the higher cancer burden and the observed disparities is
not clear and warrant further exploration.
There are no national cancer screening programs in TT.
However, the results from a population-based prostate
cancer screening in Tobago between September 1997 and
June 2001 are particularly worth noting. Here screening
for prostate cancer using serum prostate-specific antigen
(PSA) and digital rectal exam (DRE) revealed a very high
prevalence of clinically-detected prostate cancer [39].
While it is true that increased prostate cancer screening
leads to higher incidence, data support the hypothesis that
populations of African descent share genetic and/or lifestyle factors that underlie an elevated prostate cancer risk
[40, 41]. A recent study compared the effect of birthplace
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on prostate cancer risk comparing US-born men and men
from two Caribbean countries (Guyana and TT) [19]. This
study found that Caribbean-born men were diagnosed at
an older age and had worse 5-year survival than US-born
men, although among Caribbean-born men who immigrated to the US, 5-year survival was similar to that of
US-born African American men [19]. A similar study of
breast cancer reported lower survival among Caribbean
women of African ancestry living in the Caribbean compared to those who migrated to the US, compared to
US-born African American women [15]. This gap could
be due to the intersection of screening, health literacy,
tumor biology, genomics, and patterns of care issues [42].
This study has certain limitations, perhaps the greatest
of which was the limited quality of cancer surveillance
data currently available on the TT population. For example, large proportions of data on cancer stage were
missing and molecular subtype for breast cancer, for example was not reported, which precludes interpretation
of some of the study’s findings. There are issues related
to the data validity that can be addressed by an increase
in the quality of the data collected and improved steps
to have its data included in Cancer Incidence in Five
Continents. While the average DCO cases of 18.44% falls
below the threshold set by IARC for inclusion in Cancer
Incidence in Five Continents [43], it still reflects a need
for the TT cancer registry to improve data validity. Fluctuations in data quality over the study period might have
impacted some of the trends we report. This further
highlights the need to strengthen the capacity of the
registry. Another limitation was the inability to access
and examine cancer screening data, which would be an
important consideration in terms of the mortality disparities reported herein. It is plausible that disparities in
cancer mortality were associated with disparities in access and utilization of cancer screening tests, because of
differences in socioeconomic status, geography and/or
other factors. Furthermore, under the equal access to
care model in TT, initiation and receipt of optimal cancer treatment, as well as cancer care overall, may be
dependent upon a patient’s place of residence, and therefore related to differences in resource allocation by
RHAs. Another limitation was the lack of information
on where patients sought cancer care (i.e., within the
catchment area of their assigned RHA or elsewhere).
Cancer surveillance data collected in TT is not routinely
linked to tumor clinicopathological data leading to compromised data accuracy, utility and quality. Additionally,
TT does not have electronic health records, further limiting the availability for this detailed cancer data. Similar
to National Cancer Institute’s Surveillance, Epidemiology
and End Results (SEER) registries, data on behavioral
characteristics of cancer cases are not included in the
TT cancer registry. This highlights the need for
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improved cancer surveillance that can accurately inform
and support cancer prevention and control initiatives
[44]. Despite these limitations, this study highlights the
need for national strategic investment in cancer epidemiology, prevention and control.

Conclusion
In conclusion, the findings of this study demonstrate that
in TT, the highest incidence and mortality rates were observed for cancers related to reproductive organs in
women, and prostate, lung and colorectal cancers among
men, with differences observed by geography and ancestry. In developed countries, prostate and breast cancer
rates are decreasing, unlike in TT, where the rates are increasing. Thus, the findings reported herein highlight the
need for national investment to improve the understanding of the epidemiology of cancer in Trinidad and Tobago,
and to ultimately guide much needed cancer prevention
and control initiatives in the near future. Cancer prevention efforts should be strategically increased, particularly
among those cancers that are attributable to lifestyle
choices. The high proportion of cancers diagnosed at distant and unknown stages, also highlights the need for improvements in cancer screening and treatment initiatives
in TT. Considering the high burden of cancer in TT, we
expect that findings from this study will inform future policies, particularly related to resource allocation across the
cancer care continuum in TT. Additionally, it is clear that
capacity-building within the cancer registry (e.g., to
mandate standardized data collection and routine molecular subtyping of tumors) is essential for improved cancer
surveillance. This will undoubtedly improve the quality of
data available for future research and will play an instrumental role in improving cancer care in TT.
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